联合检测血清CA153、CA125、CA199对乳腺癌的临床意义

Clinical Significance of Combined Analysis of CA153,CA125,and CA199 in Breast Cancer

目的探讨血清CA153、CA125、CA199联合检测对乳腺癌早期诊断的价值。方法采用化学发光法分别检测乳腺癌、乳腺良性疾病患者、体检健康者血清中CA153、CA125、CA199的水平。结果乳腺癌患者血清CA153、CA125、CA199水平均显著高于正常组和良性乳腺疾病组,差异有统计学意义(P<0.01);乳腺癌患者术后CA153、CA125、CA199含量较术前显著性下降(P<0.01),与正常组比较差异无统计学意义(P>0.05)。CA153、CA125、CA199单独检测乳腺癌的灵敏度分别为54%、36%、30%,特异性为96.6%、91.6%、93.2%,准确性为84.2%、75.1%、74.8%。三者联合检测乳腺癌的灵敏度为78.0%、特异性为88.1%、准确性为85.2%。三项联合检测与单独检测相比灵敏度明显提高(P<0.05)。结论联合检测血清标志物CA153、CA125、CA199的阳性率、敏感性有较大幅度的提高,三项标志物虽不能作为乳腺癌的特异性指标,但可为临床早期发现、诊断乳腺癌提供十分重要的依据。

Objective To evaluate the value of combined analysis of CA153, CA125, and CA199 in the diagnosis and monitor of breast cancer. Methods Serum levels of CA153, CA125, and CA199 from breast cancer and benign breast disease patients were detected by CLIA method. Results The levels of serum CA153, CA125, and CA199 in the breast cancer group were higher than those in the benign breast diseases group and healthy group （P〈 0.01）. There was no significant difference in the levels of CA153, CA125, and CA199 between the healthy group and the benign breast disease group （P〉0.05）. After operation, the concentration of CA153, CA125, and CA199 in the breast cancer group was greatly decreased （P〈0.01）. The sensitivity of CA153, CA125, and CA199 in the breast cancer group was 54%, 36%, and 30%, respectively. The specificity was 96.6%, 91.6%, and 93.2%, respectively. The accuracy was 84.2%, 75.1%, and 74.8%, respectively. In the combined analysis of CA153, CA125, and CA199, the sensitivity rate was 78%, the specificity rate was 88.1%, and the accuracy rate was 85.2%. Conclusion Combined analysis of CA153, CA125, and CA199 greatly increase the sensitivity and positive rate of early diagnosis of breast cancer.